Fig. 1: MDS cohort overview according.

A Distribution of subsets within MDS patients according to WHO 2022 dependent on the presence of ring sideroblasts (RS). B Frequency of mutations in splicing genes SF3B1, SRSF2, U2AF1 or ZRSR2 within low blast MDS with RS < 15% or ≥15%. Splicing-: no mutation in splicing genes SF3B1, SRSF2, U2AF1 or ZRSR2.